(function(){var loadHandler=window['sl_{72C0429F-FC8A-44E7-B152-D6826999A52C}'];loadHandler&&loadHandler(161, '<div id="spr0_42c20c9c"><div id="spr1_42c20c9c" class="kern slide"><img id="img1_42c20c9c" src="data/img2.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_42c20c9c" class="kern slide"><div id="spr3_42c20c9c" style="left:103.125px;top:165.786px;"><img id="img0_42c20c9c" src="data/img214.png" width="513.75" height="343.5" alt=""/></div><div id="spr4_42c20c9c" style="top:91.063px;"><div style="width:0px;"><span id="txt0_42c20c9c" data-width="459.593750" style="left:132.43px;top:0.058px;">Letrozole + Trastusimab (HER2 inhibitor)</span></div><div style="width:0px;"><span id="txt1_42c20c9c" data-width="194.619141" style="left:262.91px;top:34.67px;">Advanced breast cancer</span></div></div><div id="spr5_42c20c9c" style="left:256.153px;top:518.189px;"><div style="width:0px;"><span id="txt2_42c20c9c" data-width="185.068359" style="left:7.2px;top:2.082px;">J. Huober et al. 2012 The Breast 21:27</span></div></div><div id="spr6_42c20c9c" style="top:-0.041px;"><div style="width:0px;"><span id="txt3_42c20c9c" data-width="430.718750" style="left:40.636px;top:-0.448px;">Combining endocrine treatments</span></div><div style="width:0px;"><span id="txt4_42c20c9c" data-width="270.218750" style="left:121.591px;top:37.952px;">with targeted agents</span></div></div></div></div>');})();